Thermocore Medical Systems
This article was originally published in The Gray Sheet
Venture capital arm of the Bank of Cyprus and a group of private investors provides "several" million dollars in funding for preclinical development of a thermography catheter to identify previously undetectable and high-risk areas of diseased coronary arteries. Working in cooperation with consulting firm Arthur D. Little, Thermocore will incorporate an array of sensors to map the interior of arteries on the basis of temperature variations. "Clinical data generated by an early version of such a device showed greater thermal variations in patients with unstable angina and acute myocardial infarction than in patients with normal coronary arteries," Thermocore explains in a release. The device, which would serve as a complement to angiograms, is expected to enter European trials within six to eight months and begin U.S. trials in the second half of 2002
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”